Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008090 | 1.00 | SIGMAR1 (0.54) | SIGMAR1POLBALDH1A1LMNASLC6A2 | |
| SCHEMBL23496876 | 1.00 | SIGMAR1 (0.54) | SIGMAR1POLBALDH1A1LMNASLC6A2 | |
| SCHEMBL1738860 | 0.88 | SIGMAR1 (0.53) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL8101234 | 0.88 | SIGMAR1 (0.53) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL2080509 | 0.88 | SIGMAR1 (0.53) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL22640155 | 0.86 | ALDH1A1 (0.52) | SIGMAR1POLBALDH1A1GAAMEN1 | |
| SCHEMBL22640117 | 0.86 | ALDH1A1 (0.52) | SIGMAR1POLBALDH1A1GAAMEN1 | |
| SCHEMBL6323998 | 0.84 | SLC6A2 (0.50) | SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1415727 | 0.83 | SLC6A2 (0.63) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 | |
| SCHEMBL6936570 | 0.83 | SLC6A2 (0.63) | SIGMAR1SLC6A2SLC6A4SLC6A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117659016-A | Cyclin modulators | 嘉兴优博生物技术有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024041661-A1 | CYCLIN MODULATOR | 嘉兴优博生物技术有限公司 | 2024-02-29 | — | — | WO | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | SIGMAR1 2828/4885POLB 2065/4885ALDH1A1 1144/4885 |
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | SIGMAR1 4873/4885POLB 2731/4885ALDH1A1 3733/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | SIGMAR1 1669/4885POLB 4650/4885ALDH1A1 118/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | SIGMAR1 4873/4885POLB 2731/4885ALDH1A1 3733/4885 |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | SIGMAR1 532/4885POLB 1431/4885ALDH1A1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.